RE: Another British inhaled covid therapy collaboration7 May 2021 13:10
"We are targeting a treatment that has the potential to be effective at the early phase of infection, to minimise the risk of hospitalisation and reduce the need for ventilatory support in intensive care.
...
the next stage is to develop and make batches that are stable over extended periods and can be used to test safety and tolerability in animal studies. ... Inspira’s research is still at a very early stage, ... The aim is to be ready to start efficacy testing of the COVID-19 IPX formulation in the latter half of 2022. ... Seasonality will play a role, with winter being the ideal time to recruit patients,” said McGoldrick. “We won’t be ready this coming winter in the UK, but we are targeting mid-2022 (in the Southern Hemisphere) or UK winter 2022 for our first efficacy study.”